Biotech Sector Shows Mixed Momentum as Small-Cap Therapeutics Rally After Hours; ALMS and Peers Navigate Market Sentiment

Biotech investors found reasons to cheer Monday evening as several therapeutics companies delivered impressive extended-session performance, each driven by distinct catalysts ranging from updated financial results to promising regulatory milestones.

Strong Recovery Stories Lead the Way

Inotiv, Inc. (NOTV) emerged as the session’s standout performer, rebounding powerfully with a 36.61% surge to $0.94 after suffering a significant 33.20% decline during regular trading. The recovery gained momentum following the company’s release of preliminary results for the fourth quarter and full-year 2025 periods. Management indicated Q4 revenue expectations between $137.5 million and $138.5 million, while projecting full-year revenues in the $512.5 million to $513.5 million range. This guidance appeared to restore investor confidence after the earlier selloff.

Applied Therapeutics, Inc. (APLT) demonstrated sustained momentum with a 16.89% after-hours jump to $0.33, building on the heels of an already-impressive 30.19% rally witnessed at the close. The enthusiasm appeared tied to positive reception of the company’s November 13 earnings disclosure, which revealed a meaningful contraction in quarterly net losses. Q3 losses narrowed to $19.0 million or $0.13 per share, a substantial improvement from the prior-year quarter’s $68.6 million deficit, or $0.48 per share.

Earnings-Driven Momentum Across the Sector

TELA Bio, Inc. (TELA) extended gains into after-hours trading with a 7.89% advance to $1.23, complementing a robust 14.08% session gain. The company’s November 13 earnings report highlighted encouraging operational progress, with Q3 net losses contracting to $8.6 million from $10.4 million year-over-year, while revenue climbed 9% to $20.7 million. Management raised expectations for 2025, now projecting revenue growth of at least 16% relative to the prior year. To strengthen its financial position, TELA also announced a $13.0 million registered direct offering expected to close November 17.

Alumis Inc. (ALMS) posted a 7.09% gain after hours to $5.97, extending a modest 1% regular-session appreciation. While the company’s Q3 results showed a widening net loss to $110.8 million compared to $93.1 million in the comparable prior-year quarter, there was a silver lining: the company generated $2.1 million in collaboration revenue from its licensing partnership with Kaken Pharmaceutical Co., Ltd., signaling potential future earnings contributions.

Regulatory Catalysts and Continued Interest

BioRestorative Therapies, Inc. (BRTX) rebounded sharply with an 8.06% after-hours climb to $1.34, overcoming a 6.77% intraday decline. The move followed an encouraging regulatory announcement: the company disclosed receipt of a Type B meeting designation with the U.S. Food and Drug Administration scheduled for mid-December. The meeting will address potential pathways for accelerated development of its Fast-Track-Designated BRTX-100 program, targeting chronic lumbar disc disease treatment—a catalyst that appeared to energize market participants.

Corcept Therapeutics Inc. (CORT) gained 4.90% to $78.80 after hours, reversing a modest earlier decline, though no company-specific catalysts emerged on Monday. The movement suggests underlying investor interest in the name remains intact.

These after-hours movements reflect how biotech investors continue assessing earnings quality, regulatory progress, and balance sheet strength amid ongoing market volatility in the therapeutics space.